<DOC>
	<DOCNO>NCT00110149</DOCNO>
	<brief_summary>RATIONALE : Monoclonal antibody , rituximab , block cancer growth different way . Some block ability cancer cell grow spread . Others , yttrium Y 90 ibritumomab tiuxetan , find cancer cell help kill carry cancer-killing substance without harm normal cell . Giving rituximab together yttrium Y 90 ibritumomab tiuxetan may kill cancer cell . PURPOSE : This phase II trial study well give rituximab together yttrium Y 90 ibritumomab tiuxetan work treat patient indolent non-Hodgkin 's lymphoma .</brief_summary>
	<brief_title>Rituximab Yttrium Y 90 Ibritumomab Tiuxetan Treating Patients With Non-Hodgkin 's Lymphoma</brief_title>
	<detailed_description>OBJECTIVES : Primary - Determine 12-week overall complete response rate patient indolent non-Hodgkin 's lymphoma treat rituximab yttrium Y 90 ibritumomab tiuxetan first-line treatment . Secondary - Determine 1-year event-free survival patient treat regimen . - Determine time progression time next antilymphoma therapy patient treat regimen . - Determine molecular response rate patient treat regimen . - Determine hematological non-hematological toxicity regimen patient . - Assess quality life patient treat regimen . OUTLINE : This open-label , multicenter study . Patients receive rituximab IV follow , 4 hour later , indium In 111 ibritumomab tiuxetan ( image ) IV 10 minute day 1 . If biodistribution acceptable , patient receive rituximab IV follow , 4 hour later , single dose yttrium Y 90 ibritumomab tiuxetan IV 10 minute day 7 , 8 , 9 absence disease progression unacceptable toxicity . Quality life assess baseline , week 6 , 10 , 14 , every 3 month 2 year , every 6 month 2 year . After completion study treatment , patient follow weekly 3 month , every 3 month 2 year , every 6 month 2 year . PROJECTED ACCRUAL : A total 18-28 patient accrue study within 2 year .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm indolent nonHodgkin 's lymphoma ( NHL ) , include 1 follow histologic subtypes : Grade1 2 follicular lymphoma Small lymphocytic lymphoma ( SLL ) Marginal zone Bcell lymphoma CD20positive disease confirm immunohistochemistry flow cytometry Bidimensionally measurable disease At least 1 lesion measure ≥ 2.0 cm single dimension CT scan Less 25 % bone marrow involvement lymphoma bilateral iliac crest bone marrow aspiration biopsy within past 6 week No clinically significant impaired bone marrow reserve evidence follow : Hypocellular marrow , evidence 1 following : ≤ 15 % cellularity Marked reduction bone marrow precursor Platelet count &lt; 100,000/mm^3 Absolute neutrophil count &lt; 1,500/mm^3 History fail stem cell collection Prior myeloablative therapy No great 5,000/mm^3 circulate tumor cell peripheral blood Requires antilymphoma therapy , indicate following : Systemic symptom B symptom Cytopenias Malaise Organ compromise Discomfort Pain Disfigurement Rapidly progressive disease Undue anxiety relate receive treatment No transformation intermediate highgrade NHL No known brain metastasis CNS involvement lymphoma NOTE : A new classification scheme adult nonHodgkin 's lymphoma adopt PDQ . The terminology `` indolent '' `` aggressive '' lymphoma replace former terminology `` low '' , `` intermediate '' , `` high '' grade lymphoma . However , protocol us former terminology . PATIENT CHARACTERISTICS : Age Over 18 Performance status ECOG 02 OR WHO 02 OR Karnofsky 70100 % Life expectancy More 3 month Hematopoietic See Disease Characteristics WBC ≥ 3,000/mm^3 Absolute neutrophil count ≥ 1,500/mm^3 Platelet count ≥ 100,000/mm^3 Lymphocyte count &lt; 5,000/mm^3 ( patient SLL ) Hepatic Bilirubin ≤ 2.0 mg/dL AST ALT ≤ 2.5 time upper limit normal Renal Creatinine ≤ 2.0 mg/dL OR Creatinine clearance &gt; 60 mL/min Cardiovascular No symptomatic congestive heart failure No unstable angina pectoris No cardiac arrhythmia Immunologic No antimurine antibody reactivity ( patient prior exposure murine antibody protein ) No ongoing active infection No history allergic reaction attribute compound similar chemical biologic composition yttrium Y 90 ibritumomab tiuxetan Other Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception least 1 year study treatment No active malignancy except nonmelanoma skin cancer No serious nonmalignant disease would preclude study participation No psychiatric illness social situation would preclude study compliance No uncontrolled illness PRIOR CONCURRENT THERAPY : Biologic therapy More 4 week since prior pegfilgrastim More 2 week since prior filgrastim ( GCSF ) sargramostim ( GMCSF ) Chemotherapy No prior chemotherapy Endocrine therapy Not specify Radiotherapy No prior external beam radiotherapy &gt; 25 % active bone marrow ( involved field regional ) Surgery More 4 week since prior major surgery except diagnostic surgery Other No prior systemic antilymphoma therapy No concurrent combination antiretroviral therapy HIVpositive patient No concurrent anticancer therapy No concurrent investigational agent No concurrent antilymphoma therapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2009</verification_date>
	<keyword>contiguous stage II grade 1 follicular lymphoma</keyword>
	<keyword>noncontiguous stage II grade 1 follicular lymphoma</keyword>
	<keyword>stage I grade 1 follicular lymphoma</keyword>
	<keyword>stage III grade 1 follicular lymphoma</keyword>
	<keyword>stage IV grade 1 follicular lymphoma</keyword>
	<keyword>contiguous stage II grade 2 follicular lymphoma</keyword>
	<keyword>noncontiguous stage II grade 2 follicular lymphoma</keyword>
	<keyword>stage I grade 2 follicular lymphoma</keyword>
	<keyword>stage III grade 2 follicular lymphoma</keyword>
	<keyword>stage IV grade 2 follicular lymphoma</keyword>
	<keyword>contiguous stage II marginal zone lymphoma</keyword>
	<keyword>noncontiguous stage II marginal zone lymphoma</keyword>
	<keyword>splenic marginal zone lymphoma</keyword>
	<keyword>stage I marginal zone lymphoma</keyword>
	<keyword>stage III marginal zone lymphoma</keyword>
	<keyword>stage IV marginal zone lymphoma</keyword>
	<keyword>extranodal marginal zone B-cell lymphoma mucosa-associated lymphoid tissue</keyword>
	<keyword>nodal marginal zone B-cell lymphoma</keyword>
	<keyword>contiguous stage II small lymphocytic lymphoma</keyword>
	<keyword>noncontiguous stage II small lymphocytic lymphoma</keyword>
	<keyword>stage I small lymphocytic lymphoma</keyword>
	<keyword>stage III small lymphocytic lymphoma</keyword>
	<keyword>stage IV small lymphocytic lymphoma</keyword>
</DOC>